Unique Immunotherapy Combinations Come to the Forefront at SITC MeetingJanuary 27th 2021
In this trial, the previous observation of liver toxicity using CD137 agonism was not observed, suggesting a safe neoadjuvant dosing. Indeed, 30% of patients demonstrated pathologic responses. Further research may combine a way of overcoming immune checkpoint pathways with stimulatory agonists.
Improved Safety Measures Mark Newest Treatments in Soft Tissue SarcomaJanuary 26th 2021
In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.
Phase 3 COSMIC-313 Trial Explores Triplet Therapy in Advanced Renal Cell CarcinomaJanuary 26th 2021
The safety and efficacy of cabozantinib plus nivolumab and ipilimumab versus nivolumab/ipilimumab will be evaluated in 676 treatment-naïve patients with advanced or metastatic renal cell carcinoma (RCC) in the phase 3 COSMIC-313 trial.
Urelumab Combo Leads to Improved Pathologic Response in Resectable PDACJanuary 25th 2021
Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab was observed in patients with resectable pancreatic ductal adenocarcinoma, according to findings from a 3-arm phase 1/2 trial.
MBCC Offers Review of Burgeoning Advancements in Breast Cancer ManagementJanuary 24th 2021
The virtual 38th Annual Miami Breast Cancer Conference®, hosted by Physicians’ Education Resource®, LLC will feature presentations from industry thought leaders on innovations in the arena of breast cancer treatment, including topics about systemic therapy and beyond.
How Pharmaceutical Innovation Is Saving the WorldJanuary 24th 2021
This was the fastest vaccine development program in history, and it’s not even close. David Pride, MD, PhD, a microbiologist at the University of California, San Diego, estimates that vaccines typically take 10 to 15 years to develop. Until the COVID-19 pandemic, the fastest development timeline was 4 years, for the mumps vaccine.
Efficacy of Frontline Atezolizumab Combo Is Comparable Regardless of Primary Urothelial Cancer LocationJanuary 23rd 2021
An exploratory analysis of the phase 3 IMvigor130 trial demonstrated that the benefit of frontline atezolizumab added to gemcitabine and platinum chemotherapy was maintained in patients with urothelial cancer, regardless of the site of the primary tumor.
Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, MelanomaJanuary 22nd 2021
Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma and melanoma received the combination of eganelisib and nivolumab.
New Metastatic Cervical Cancer Treatments Give HopeJanuary 21st 2021
Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.
Complications of Coagulopathy Caused by COVID-19 Puts Patients With Cancer at RiskJanuary 21st 2021
Subsequent observations related to the COVID-19 have led to the discovery cardiac manifestations, gastrointestinal complications, and hematological manifestations associated with this virus.